Diagnostic and therapeutic applications of radiopharmaceutical agents: The medical use of radioactive iodine (I-131) therapy for hyperthyroidism treatments.

2021 ◽  
Vol 3 (1) ◽  
Author(s):  
Hasnae WATLA ◽  
Mohamed LAHKIM ◽  
Mohamed Amine CHAD
Keyword(s):  
Nuclear Medicine ◽  
Effective Dose ◽  
Radioactive Iodine ◽  
Minimum Effective Dose ◽  
Therapeutic Aspect ◽  
Therapeutic Applications ◽  
Medical Centers ◽  
Iodine 131 ◽  
Radiopharmaceutical Agents

The treatment of hyperthyroidism with iodine-131 has been recognized on nuclear medicine as simple, effective and inexpensive, this kind of radiopharmaceutical is chosen by the majority of medical centers by administering a minimum effective dose enabling euthyroidism to be easily compensated as quickly as possible while avoiding radiation problems. In this mini_review, we are going to explain the diagnostic and therapeutic aspect of radiopharmaceuticals by taking an example of radioiodine I-131 and its role on hyperthyroidism treatment .

Radiation exposure of patients undergoing nuclear medicine procedures in Germany between 1996 and 2000

2005 ◽  
Vol 44 (05) ◽  
pp. 119-130 ◽  
Author(s):  
P. Schnell-Inderst ◽  
D. Noßke ◽  
M. Weiss ◽  
A. Stamm-Meyer ◽  
G. Brix ◽  
...  
Keyword(s):  
Nuclear Medicine ◽  
Cardiovascular System ◽  
Effective Dose ◽  
Current Status ◽  
Annual Number ◽  
Statistical Parameters ◽  
Public Health Information ◽  
Nuclear Medicine Procedures ◽  
And Gender ◽  
Icrp Publication

Summary:The aim of this study was to estimate both the frequency and effective dose of nuclear medicine procedures performed in Germany between 1996 and 2000 for different subgroups of patients. Methods: Electronically archived data from 14 hospitals and 10 private practices were restored and statistically analyzed. The effective dose per examination was calculated according to ICRP publication 80 using the tissue weighting factors given in ICRP publication 60. Based on the data collected, statistical parameters were computed to characterize the frequency and effective dose of the various nuclear medicine procedures. Results: In total, 604,771 nuclear medicine procedures performed in 433,709 patients were analyzed. On average, 1.4 examinations were carried out per patient and year. The median effective dose was 1.7 [5.-95. percentile; mean: 0.4–8.5; 2.9] mSv per examination and 2.3 [0.5–11.2; 3.5] mSv per patient. Interestingly, the mean effective dose per examination, but not the number of examinations per year increased with the age of the patients. Most frequent were examinations of the thyroid (36.7%), the skeleton (27.1%) and the cardiovascular system (11.1%), which were associated with a median effective dose of 0.5 [0.5–1.1; 0.7] mSv, 3.4 [2.9–5.1; 3.6] mSv and 7.3 [3.2–21.0; 9.5] mSv, respectively. Over the five-year period examined, the total annual number of PET procedures (222.3%) as well as of examinations of thyroid (24.5%), skeleton (17.9%), and the cardiovascular system (14.9%) increased markedly, whereas a decrease was observed for brain (-39.3%), lung (-20.2%) and renal (-15.0%) scans. Conclusion: The age- and gender-specific data presented in this study provide detailed public health information on both the current status and recent trends in the practice of diagnostic nuclear medicine examinations.

Radiation exposure of the staff at the therapeutic and diagnostic nuclear medicine department

2008 ◽  
Vol 47 (04) ◽  
pp. 175-177 ◽  
Author(s):  
J. Dolezal
Keyword(s):  
Nuclear Medicine ◽  
Radiation Exposure ◽  
Effective Dose ◽  
Radiation Protection ◽  
Annual Effective Dose ◽  
Protection Measures ◽  
Professional Groups ◽  
Personal Dosimetry ◽  
The Mean ◽  
Administered Activity

SummaryAim: To assess a radiation exposure and the quality of radiation protection concerning a nuclear medicine staff at our department as a six-year retrospective study. Therapeutic radionuclides such as 131I, 153Sm, 186Re, 32P, 90Y and diagnostic ones as a 99mTc, 201Tl, 67Ga, 111In were used. Material, method: The effective dose was evaluated in the period of 2001–2006 for nuclear medicine physicians (n = 5), technologists (n = 9) and radiopharmacists (n = 2). A personnel film dosimeter and thermoluminescent ring dosimeter for measuring (1-month periods) the personal dose equivalent Hp(10) and Hp(0,07) were used by nuclear medicine workers. The wearing of dosimeters was obligatory within the framework of a nationwide service for personal dosimetry. The total administered activity of all radionuclides during these six years at our department was 17,779 GBq (99mTc 14 708 GBq, 131I 2490 GBq, others 581 GBq). The administered activity of 99mTc was similar, but the administered activity of 131I in 2006 increased by 200%, as compared with the year 2001. Results: The mean and one standard deviation (SD) of the personal annual effective dose (mSv) for nuclear medicine physicians was 1.9 ± 0.6, 1.8 ± 0.8, 1.2 ± 0.8, 1.4 ± 0.8, 1.3 ± 0.6, 0.8 ± 0.4 and for nuclear medicine technologists was 1.9 ± 0.8, 1.7 ± 1.4, 1.0 ± 1.0, 1.1 ± 1.2, 0.9 ± 0.4 and 0.7 ± 0.2 in 2001, 2002, 2003, 2004, 2005 and 2006, respectively. The mean (n = 2, estimate of SD makes little sense) of the personal annual effective dose (mSv) for radiopharmacists was 3.2, 1.8, 0.6, 1.3, 0.6 and 0.3. Although the administered activity of 131I increased, the mean personal effective dose per year decreased during the six years. Conclusion: In all three professional groups of nuclear medicine workers a decreasing radiation exposure was found, although the administered activity of 131I increased during this six-year period. Our observations suggest successful radiation protection measures at our department.

The minimum effective dose of praziquantel in treatment of Hymenolepis diminuta in rats

1995 ◽  
Vol 69 (1) ◽  
pp. 91-92 ◽  
Author(s):  
P.C. Fan ◽  
A. Ito
Keyword(s):  
Effective Dose ◽  
Hymenolepis Diminuta ◽  
Minimum Effective Dose ◽  
Faecal Examination ◽  
Faecal Samples

AbstractTo determine the minimum effective dose of praziquantel against Hymenolepis diminuta in rats, 5.0 mg/kg, 2.5 mg/kg, 1.0 mg/kg, 0.5 mg/kg, 0.1 mg/kg, or 0.05 mg/kg praziquantel were given to each of five experimentally infected rats in six groups. Faecal samples from each rat were examined for worms on day 10. Based on the results of faecal examination and autopsy, the minimum effective dose of praziquantel against Hymenolepis diminuta in rats was determined to be 0.5 mg/kg.

scholarly journals Outcome of Fixed Dose of Radioiodine Therapy in Hyperthyroid Patients at NINMAS

2018 ◽  
Vol 20 (1) ◽  
pp. 37
Author(s):  
Sharmin Quddus ◽  
Fatima Begum ◽  
Nasreen Sultana ◽  
Rahima Perveen ◽  
Tapati Mandal ◽  
...  
Keyword(s):  
Nuclear Medicine ◽  
Single Dose ◽  
Thyroid Function ◽  
Radioactive Iodine ◽  
Radioiodine Therapy ◽  
Thyroid Stimulating Hormone ◽  
Fixed Dose ◽  
Free Triiodothyronine ◽  
Toxic Goiter ◽  
Hyperthyroid Patients

<p><strong>Objective:</strong> The modified fixed doses of radioactive iodine (RAI) in different types of hyperthyroidism had been practiced at National Institute of Nuclear Medicine &amp; Allied Science (NINMAS) according to Society of Nuclear Medicine Bangladesh (SNMB) protocol since 2002 which was upgraded in 2015. The objective of the study was to observe the treatment outcome in modified fixed dose on previous protocol. Patients and Methods: In the present study the outcome of radioiodine therapy of hyperthyroid patients was retrospectively evaluated in 1349 consecutive primary hyperthyroid patients treated from January 2010 to December 2014 at NINMAS. Diagnosis of hyperthyroidism was done by thyroid function test; thyroid stimulating hormone (TSH), free triiodothyronine (FT3)   &amp; free thyroxine (FT4), 99m Technetium scan, thyroid radioiodine uptake and ultrasound imaging of thyroid gland. All patients received a fixed dose (8-29 m Ci) of radioactive iodine (RAI) depending on types of hyperthyroidism, visual assessment of gland size and severity of disease at diagnosis. They were followed up at 2 months of therapy, then every three months intervals for first year and thereafter 6 monthly up to 5 years or as needed during fluctuation of thyroid function.</p><p><strong>Results:</strong> Among the study population, 832 patients had diffuse toxic goiter (Graves’ disease), 369 patients were diagnosed as toxic multinodular goiter and 148 patients with single toxic nodule. At one year follow-up, permanent hypothyroidism occurred in 61.62% of patients and the cumulative incidence of hypothyroidism progressively increased up to 79.25% after 5 years. Cure or success of RAI therapy was considered as attainment of euthyroid state or hypothyroid state. About 11.26 % patients received more than single dose.</p><p><strong>Conclusion:</strong> Fixed dose RAI therapy is very much cost effective mode of treatment for primary hyperthyroidism with ~89% success by giving single dose.</p><p>Bangladesh J. Nuclear Med. 20(1): 37-40, January 2017</p>

Sign in / Sign up

Export Citation Format

Share Document